Cambrex broke ground on a $120 million expansion of its Charles City, Iowa, plant on Oct. 29, adding to a pharmaceutical manufacturing campus that just turned 100 years old. The project is expected to boost the facility's total manufacturing capacity by about 25%, with completion targeted for the fourth quarter of 2028.
The company detailed the expansion in a news release, saying the new construction will add 160,000 liters of manufacturing capacity to the site, pushing its total capacity to nearly one million liters, according to Cambrex's announcement. The new capacity is intended to support both development work and commercial-scale manufacturing of small-molecule active pharmaceutical ingredients and synthetic peptides, the company said. As The Des Moines Register reported, the expansion lands at a 100-year-old, 45-acre facility that has anchored the small North Iowa city for a century.
Claudio Russolo, Cambrex's chief operating officer and incoming CEO, framed the groundbreaking as part of a broader manufacturing push. “This groundbreaking marks an important milestone in our continued investment in U.S. manufacturing and in the Charles City site,” Russolo said in the company's release.
Jobs Numbers Remain a Moving Target
What the expansion means for local hiring is harder to pin down, and reports have told conflicting stories as the project evolved. The Register's report notes plainly that Cambrex has not shared whether the expansion will add jobs at all. Earlier reporting, however, offered a range of projections: a March report from the same outlet that broke the project's initial planning said Cambrex expected to add at least 30 new positions, according to NJBIZ, while a local North Iowa outlet put the figure between 50 and 100 new jobs, per the Globe Gazette. Separately, earlier coverage tied to the project's state incentive package cited a planned 104 jobs tied to what was then described as a $150 million capital investment, according to KIMT. Those figures don't reconcile with each other or with the $120 million, 25%-capacity-growth project Cambrex announced at the groundbreaking, and nothing in the available reporting explains whether the scope changed or which numbers are current.
A Century-Old Plant With Deep Expansion History
The Charles City site has a long track record of incremental growth. A 2020 report from Chemical & Engineering News described a previous expansion there as the facility's third in eight years, part of a pattern of steady reinvestment at the plant. Cambrex is based in East Rutherford, New Jersey, and employs about 400 people in Charles City, according to the company's website.
The Iowa project also fits into a larger company strategy. NJBIZ reported that in 2024, Cambrex added more than 150,000 square feet of capacity across its North American and European network as part of a five-year, $100 million investment plan, and the company is separately investing $30 million to expand its site in Milan, Italy, with that project expected to wrap in the second half of 2027.
Industry-Wide Push for U.S. Drug Manufacturing
The Charles City build-out arrives as pharmaceutical and chemical manufacturers face pressure to shift more production stateside. Chemical & Engineering News reported in 2025 that major drug companies have been pledging increased investment in U.S. manufacturing capacity, a trend the Iowa expansion appears to track. Cambrex also received state support for the project: according to an Iowa legislative document, Cambrex Charles was listed for a $7.6 million Investment Tax Credit and a $2.5 million sales and use tax refund, though the full terms and approval status of those incentives were not detailed in the available excerpt.
State economic development figures cited by KIMT put the Cambrex project in a broader context of Iowa manufacturing investment. The agency has approved awards for 16 manufacturing projects statewide expected to support at least 1,170 jobs and drive nearly $775 million in new capital investment, according to the outlet's reporting. For now, Cambrex says the expanded Charles City plant will continue the site's work developing active ingredients and new drugs, producing small test batches before scaling up to the large commercial quantities that eventually reach pharmacy shelves — even as the project's exact employment impact remains unconfirmed.
